Oncology

How is the breast cancer landscape evolving, from HER2-low breakthroughs to the future of targeted therapy and precision care?

How if scientific innovation transforming precision oncology? Simon Lord, Associate Professor in Experimental Cancer Therapeutics at the University of Oxford shares his expertise.

Stephen Freedland explores how lifestyle, equity, and emerging therapeutics are reshaping prostate cancer care, from risk to survivorship.

In this episode Jonathan is joined by Jean Abraham, to delve into the future of integrated cancer medicine, the evolving role of clinical trials, and how precision oncology is redefining outcomes for patients with breast cancer across the UK.

Lennard Lee, Associate Professor of Cancer Vaccines at the University of Oxford, shares how large-scale collaboration is shaping the future of cancer vaccines and oncology innovation.

Bradley Monk, Medical Director of Late-Phase Clinical Research at Florida Cancer Specialists, shares key understandings from the Society of Gynecologic Oncology (SGO) 2025, alongside a fascinating deep dive into drug approval and access.

Bradley Monk, Medical Director of Late-Phase Research at Florida Cancer Specialists, shares his insights from ESGO 2025 and landmark studies in gynaecologic oncology.

Joan Carles, Vall d’Hebron, shares insights on anti-angiogenic therapies, resistance in GU cancers, and the future of personalised oncology.